Polarean Imaging PLC
LSE:POLX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Polarean Imaging PLC
Cash & Cash Equivalents
Polarean Imaging PLC
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Polarean Imaging PLC
LSE:POLX
|
Cash & Cash Equivalents
$7.3m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash & Cash Equivalents
$2B
|
CAGR 3-Years
51%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
19%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Cash & Cash Equivalents
$2.9B
|
CAGR 3-Years
50%
|
CAGR 5-Years
20%
|
CAGR 10-Years
19%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash & Cash Equivalents
$4B
|
CAGR 3-Years
30%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash & Cash Equivalents
$8.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
10%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash & Cash Equivalents
$3.4B
|
CAGR 3-Years
29%
|
CAGR 5-Years
16%
|
CAGR 10-Years
17%
|
|
Polarean Imaging PLC
Glance View
Polarean Imaging Plc.operates as a medical drug-device combination company serving the medical imaging market in the United States and internationally. The company is headquartered in Durham, North Carolina and currently employs 21 full-time employees. The company went IPO on 2018-03-29. The firm with its subsidiaries operates in the medical imaging market and develops equipment to enable existing magnetic resonance imaging (MRI) systems. The firm develops equipment that enables existing MRI systems to attain an improved level of pulmonary function imaging and specializes in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualize ventilation. 129Xe gas is being studied for visualization of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream. 129Xe used to evaluate pulmonary function and to visualize the lung using MRI. The firm operates in an area of unmet medical need and its technology provides an investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform.
See Also
What is Polarean Imaging PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
7.3m
USD
Based on the financial report for Jun 30, 2025, Polarean Imaging PLC's Cash & Cash Equivalents amounts to 7.3m USD.
What is Polarean Imaging PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-5%
Over the last year, the Cash & Cash Equivalents growth was -52%. The average annual Cash & Cash Equivalents growth rates for Polarean Imaging PLC have been -32% over the past three years , -5% over the past five years .
